Tech Company M&A Transactions
StroMedix Acquisition
StroMedix was acquired by Biogen. The transaction was announced on 2/14/2012. Biogen disclosed that the acquisition price was $562.5 million.
Transaction Overview
Company Name
Acquired By
Announced On
2/14/2012
Transaction Type
M&A
Amount
$562,500,000
M&A Terms
Under the terms of the agreement, Biogen Idec will make an upfront cash payment of $75 million and additional contingent value payments of up to $487.5 million based on the achievement of certain development and approval milestones across multiple indications.
Company Information
Company Status
Acquired or Merged
Industry
Medical Devices & Instruments
Mailing Address
One Canal Park 1120
Cambridge, MA 02141
USA
Cambridge, MA 02141
USA
Phone
Website
Email Address
Overview
Stromedix is a clinical-stage biotechnology company committed to developing novel drugs to treat fibrotic organ failure. Stromedix will focus initially on chronic indications but plans to leverage its expertise and expand its therapeutic pipeline into related settings such as acute organ failure and cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Dan Lynch
Chief Executive Officer
Michael Gilman
Chief Medical Officer
Brad Maroni
VP - R & D
Shelia Violette
Browse more venture capital transactions:
Prev: 2/14/2012: Novinda venture capital transaction
Next: 2/14/2012: PerfectServe venture capital transaction
Share this article
News on VC Transactions
We record tech company VC transactions. All VC database entries reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs